Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters
Database
Language
Publication year range
1.
Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.
Prestes, Daniel P; Arbona, Esther; Nevett-Fernandez, Alexandra; Woolley, Ann E; Ho, Vincent T; Koo, Sophia; Baden, Lindsey R; Koreth, John; Hammond, Sarah P; Issa, Nicolas C; Marty, Francisco M.
Clin Infect Dis ; 65(3): 510-513, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28419210

ABSTRACT

Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.


Subject(s)
Antineoplastic Agents/adverse effects , Cytomegalovirus Infections/epidemiology , Cytomegalovirus , Dasatinib/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Adult , Aged , Antineoplastic Agents/therapeutic use , Cohort Studies , Cytomegalovirus Infections/chemically induced , Dasatinib/therapeutic use , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Young Adult
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL